The applicant name appears on PMA supplements for implantable defibrillators with and without cardiac resynchronization therapy, and for a drug-eluting pacing lead. The supplied collection holds twelve PMA-linked records, with five approvals and seven 30-day notices; the smaller record sample of five entries shows two approvals and three 30-day notices. Those figures describe the supplied filings only, not company sales, total portfolio or safety performance. [1][2][5]
Labeling and nominal-setting supplements for Cobalt devices
Two approvals dated November 4, 2026 cover labeling updates and a change to nominal settings for the Intrinsic Antitachycardia Pacing (iATP) feature in applicable Cobalt devices. P010031/S931 covers Cobalt MRI CRT-D, Cobalt XT MRI CRT-D and Crome MRI CRT-D under product code NIK; P980016/S964 covers Cobalt MRI ICD, Cobalt XT MRI ICD and Crome MRI ICD under product code LWS. Both were received August 6, 2026 on the Normal 180 Day Track with a labeling-change supplement reason. [1][2]
The FDA record pages for these two supplements carry only database navigation and agency contact material, so the substantive scope rests on the PMA entries themselves. [7][10]
Manufacturing process notices
Two 30-day notices decided October 29, 2026 address a process change for manufacturer, sterilizer, packager or supplier. P010031/S934 covers the CRT-D family and adjusts the rise time measurement upper limit during final functional electrical testing; P980016/S967 applies the same adjustment to the ICD family. Both were received October 2, 2026. [3][4]
A third 30-day notice, P030036/S162 decided October 16, 2026, covers the Medtronic SelectSecure lead Model 3830, a drug-eluting permanent right ventricular or right atrial pacemaker electrode under product code NVN, and modifies the manufacturing method for the inner assembly stringing process. It was received September 23, 2026. [5]
Documented device features
Medtronic's Cobalt XT MRI SureScan CRT-D product page lists SmartShock 2.0 technology, Intrinsic ATP and Reactive ATP algorithms, EffectivCRT during AF and EffectivCRT diagnostic, AdaptivCRT, OptiVol 2.0 fluid status monitoring, TriageHF technology, PhysioCurve design and MRI SureScan at 1.5 and 3 tesla. The Cobalt MRI SureScan CRT-D page lists a narrower set including SmartShock 2.0, Reactive ATP, AdaptivCRT, OptiVol 2.0, PhysioCurve and MRI SureScan. [6][8]
A Cobalt XT HF Quad CRT-D MRI SureScan specification sheet for model DTPA2QQ lists BlueSync technology, TriageHF compatibility, Reactive ATP, AdaptivCRT, EffectivCRT diagnostic and EffectivCRT during AF, SmartShock 2.0+ with intrinsic ATP, 1.5T and 3T MRI access when MR conditions for use are met, PhysioCurve, OptiVol 2.0 and a DF4 connector. These are publisher-stated product features, not independent findings. [9]
Applicant identity and filing scope
The applicant name on each cited filing is Medtronic Cardiac Rhythm Disease Management, with a Mounds View, Minnesota mailing address in the FDA records; that address is a filing address and is not treated here as a headquarters. The public information does not establish a parent or brand relationship beyond the applicant name itself, and no ownership claim is made. [1][5]
The collection is limited to PMA pathway records; no recall records appear in the supplied sample. Device classes in the cited entries are class 3, and the advisory committee is cardiovascular for each. [2][3]










